Arthneeti
Tarsons Products LtdQ2 FY25

Tarsons Products Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹331.2P/E: 148.8Market Cap: ₹1.8K CrSector: Healthcare Equipment & Supplies

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 0 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

No information is provided regarding the same in the latest conference call.

See what Tarsons Products Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No information is provided regarding the same in the latest conference call.

See what Tarsons Products Ltd management said on order book — free account, 30 seconds.

Capex plans

No information is provided regarding the same in the latest conference call.

Track Tarsons Products Ltd — get its next earnings analysis in your feed

How does Tarsons Products Ltd rank vs peers in Healthcare Equipment & Supplies?

Pro feature
ThisTarsons Products Ltd
See where Tarsons Products Ltd sits in Healthcare Equipment & SuppliesSee which companies these are, and every other name in the sector.Open rankings

How does Tarsons Products Ltd rank in Healthcare Equipment & Supplies?

Compare Tarsons Products Ltd against every Healthcare Equipment & Supplies company (Q2 FY25) on revenue, margins and earnings-call signals.

View Healthcare Equipment & Supplies leaderboard →

Continue your research

What Tarsons Products Ltd's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

  • QMS Medical Allied Services Ltd (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹37.3 crore . Key investor presentation takeaways from QMS Medical Allied Services Ltd's Q3 FY26 investor presentation — and how

  • Avience Biomedicals Ltd (Q1 FY27)

    New manufacturing facility has capacity to support peak revenue of around ₹250–265 crore, subject to product mix and approvals. Key concall takeaways from…

  • Fischer Medical Ventures Ltd (Q2 FY25)

    EBITDA: ₹36.3 crore, a 45.5% year-on-year increase. Key concall takeaways from Fischer Medical Ventures Ltd's Q2 FY25 earnings call — and how it ranks against…

  • Fischer Medical Ventures Ltd (Q1 FY27)

    The provided pages of the investor presentation do not contain any specific revenue, sales, or volume figures for the quarter, nor details on year-on-year…

Compare:vs Molbio Diagnostivs Fischer Medical Ventures Ltdvs Q-Line Biotech Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →